Timeline: Insulin Market Under Scrutiny
A flurry of federal and state probes have targeted insulin manufacturers and pharmacy benefit managers ā middlemen in the prescription drug-pricing pipeline. Here, we connect the legal dots.
Drug Costs
581-600 of 704 results
-
-
Flurry Of Federal And State Probes Target Insulin Drugmakers And Pharma Middlemen
Over the past two years, a powerful federal prosecutor and several state attorneys general have launched investigations related to diabetes drugs.
-
New Law Challenges ‘Evils’ Of Pharma Profits, California Governor Claims
Gov. Jerry Brown signed the measure, which takes effect next year and will require drug companies to publicly justify big price increases.
-
Eyes Fixed On California As Governor Ponders Inking Drug Price Transparency Bill
"If it gets signed by this governor, it's going to send shock waves throughout the country,ā one legislator says. Pharma has spent $16.8 million lobbying against this bill and other drug laws in California.
-
Hepatitis C Drugās Lower Cost Paves Way For Medicaid, Prisons To Expand Treatment
The drug, sold under the name Mavyret, can cure all six genetic types of the liver disease in eight weeks at a cost of $26,400, well below other options.
-
Do Pharma’s Claims On Drug Prices Pass The Smell Test? We Found 5 Stinkers.
Drug companies are in the midst of a glossy publicity campaign to stop attempts to control rising pharma costs. But the devil is in the details.
By Jay Hancock -
Absent Federal Action, States Take The Lead On Curbing Drug Costs
Congress has yet to take substantive action on this growing consumer concern, but a number of states are flexing their cost-control muscle.
-
Out-Of-Pocket Costs Often Keep Pricey New Cholesterol Drugs Out Of Reach, Study Finds
Research published this week by JAMA Cardiology analyzed pharmacy claims data related to a new class of cholesterol-lowering drugs.
-
Right After Trump Blamed High Drug Prices On Campaign Cash, Drugmakers Gave More
At a political rally in March, President Donald Trump said drug prices are āoutrageousā and blamed campaign contributions. Drugmakers funneled nearly $280,000 to Congress the very next day.
By Sydney Lupkin and Elizabeth Lucas -
News Analysis
Everyone Says We Must Control Exorbitant Drug Prices. So, Why Donāt We?
Any momentum to address prescription drug costs has been lost amid rancorous debates over replacing Obamacare and stalled by roadblocks erected via lobbying and industry cash.
By Jay Hancock -
High On Drugs? Anthem Cites Soaring Drug Costs To Justify 35% Rate Hike in California
The companyās drug spending prediction, far above other insurers in the individual market, has experts scratching their heads. Anthem cites market volatility.
ĢżBy Chad Terhune -
The Orphan Drug Machine
FDA Moves To Guard Against Abuse Of āOrphan Drugā Program
Following a KHN investigation, the Food and Drug Administration has moved to speed up approvals of āorphan drugsā while closing a loophole that allowed drugmakers to skip pediatric testing.
-
Facebook Live: The Prescription Drug Pricing Pipeline
In this Facebook Live, KHNās Julie Appleby talks with Stephanie Stapleton and answers readersā questions about the prescription drug pricing pipeline and the industry stakeholders who have a role in what you pay.
-
āBreakthroughā Leukemia Drug Also Portends āQuantum Leapā In Cost
A genetically altered cancer drug, based on CAR T-cell therapies, could be a big success with leukemia patients but at a staggering cost.
By Liz Szabo -
Podcast: ‘What The Health?’ Why Is It So Difficult To Control Drug Prices?
In this episode of āWhat the Health?ā Mary Agnes Carey of Kaiser Health News, Sarah Karlin-Smith of Politico, Margot Sanger-Katz of The New York Times and Julie Appleby of Kaiser Health News discuss the recent extension of cost-sharing subsidies for millions of low-income beneficiaries on the Affordable Care Actās marketplaces and the state of play on Capitol Hill and in the states concerning initiatives to lower prescription drug costs.
-
Climbing Cost Of Decades-Old Drugs Threatens To Break Medicaid Bank
Medicaid spent billions more in 2016 than the year before on decades-old prescription drugs, including many generics, a Kaiser Health News data analysis shows.
-
Hospitals Slashed Use Of Two Heart Drugs After Huge Price Hikes
Hospital use of two popular heart medicines, nitroprusside and isoproterenol, dramatically dropped after the prices for both soared.
-
Taking A U-Turn On Benefits, Big Employers Vow To Continue Offering Health Insurance
Three years ago, only about a quarter of the nationās large employers were very confident they would have a health plan in 10 years. That number has now risen to 65 percent.
By Jay Hancock -
Denial, Appeal, Approval ā¦ An Adultās Thorny Path To Spinraza Coverage
The FDA granted approval for Spinraza in late December for use on children and adults with spinal muscular atrophy. Insurance coverage is mostly focused on infants and children.
-
Drug Puts A $750,000 āPrice Tag On Lifeā
The high cost of Spinraza, a new and promising treatment for spinal muscular atrophy, highlights how the cost-benefit analysis insurers use to make drug coverage decisions plays out in human terms.